Trial Profile
Investigating the clinical use of 13-valent pneumococcal conjugate vaccine (Prevenar) in childhood acute lymphoblastic leukaemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2019
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PCV13 in ALL
- 05 Oct 2019 Results published in the Clinical Infectious Diseases
- 06 Dec 2013 Accrual to date is 85% according to United Kingdom Clinical Research Network.
- 23 Nov 2013 Accrual to date is 84% according to United Kingdom Clinical Research Network.